Allergo

Quick links to important sections

Allergo

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allergo

Allergo: Classification and Pharmacological Identity

Allergo is a synthetic drug classified within the pharmacological class of antihistamines, specifically acting as a Histamine H1-receptor antagonist. The primary active ingredient of this systemic therapeutic agent is Fexofenadine hydrochloride. Fexofenadine is identified as a second-generation antihistamine. This compound is chemically defined as a piperidine derivative and the active terfenadine metabolite. Its function in blocking the effects of histamine in the body is utilized for managing reactions linked to histamine release.

Composition, Forms, and General Purpose

The composition of Allergo is based on the single active substance, Fexofenadine hydrochloride, making it a single product monotherapy. This medicine is characterized by its non-sedating profile, positioning it for patients who require relief without impacting alertness. It is available in various pharmaceutical preparations for oral administration, including the film-coated tablet, standard tablet, and an oral suspension, allowing for delivery across a broad target audience. The general therapeutic purpose of this H1-receptor antagonist is to provide symptomatic relief by mitigating the action of histamine, which contributes to easing the overall discomfort associated with typical allergy symptoms.

What side effects are possible with Allergo?

Possible side effects and safety information

The official safety profile for Allergo (Fexofenadine hydrochloride) details adverse reactions observed during clinical trials and post-marketing surveillance, categorized by the frequency of occurrence and the physiological system affected, in alignment with regulatory documents.


Frequency-Classified Adverse Reactions

The following effects are officially classified:

  • Common (occurring in at least 1 in 100 patients): Adverse events reported in the Nervous System Disorders include headache, drowsiness, and dizziness. Nausea is also common in Gastrointestinal Disorders.
  • Uncommon (occurring in less than 1 in 100): Fatigue.
  • Not Known (Post-marketing, frequency cannot be estimated): Reports include insomnia, nervousness, sleep disorders, nightmares/excessive dreaming (paroniria), diarrhea, rash, urticaria, pruritus, tachycardia, and palpitations.

Serious Reactions and Safety Constraints

Rare but serious Hypersensitivity reactions have been documented through post-marketing surveillance, including manifestations such as systemic anaphylaxis, angioedema, chest tightness, and dyspnoea (difficulty breathing). Cardiac disorders like tachycardia and palpitations have also been reported.

Safety characteristics have led to constraints in specific patient groups. Caution is required for use in older adults and those with renal impairment, as the drug's elimination half-life may be prolonged, increasing systemic concentration. Additionally, the absorption of Fexofenadine may be reduced when taken with aluminum/magnesium-containing antacids or consumed with specific fruit juices (e.g., apple, orange, grapefruit).

Overdose and Emergency Response

The official regulatory documents state that information regarding acute overdose of fexofenadine hydrochloride is limited. The documented manifestations are consistent with an exaggeration of known effects, primarily affecting the central nervous system.

Overdose Scope Official Regulatory Statement
Documented Overdose Presentations Symptoms include dizziness, drowsiness, dry mouth, and fatigue.
Physiological Systems Affected Primarily CNS effects (drowsiness, dizziness, fatigue) and mucosal effects (dry mouth).
Population-Specific Overdose Notes Caution is advised for elderly, renally impaired, or hepatically impaired patients due to limited data and potential for prolonged clearance.

Emergency-Response Statements

Regulators mandate that in the event of a suspected or confirmed overdose, you must seek immediate medical attention. The official management protocol for fexofenadine is symptomatic and supportive, as no specific antidote is known. Standard clinical measures should be considered to remove any unabsorbed product. A key limitation noted is that haemodialysis does not effectively remove fexofenadine hydrochloride from the blood.

Connection to the overall overdose profile

The regulatory overdose profile is defined by reported amplified non-serious effects and the clear mandate for immediate medical attention. Management is constrained by the lack of an antidote, necessitating procedural steps for unabsorbed product removal and reliance on supportive care, with the explicit confirmation that haemodialysis is ineffective.

Therapeutic Uses of Allergo

What Allergo Treats: Main Uses and Benefits

Symptom Domains and Therapeutic Support

The medication is relevant for easing certain distressing symptoms, including those related to allergy and dermatological support. It is commonly used to help with symptomatic relief for conditions involving episodic or fluctuating manifestations like seasonal allergic rhinitis, perennial rhinitis, and chronic idiopathic urticaria (hives).

This agent is applied in addressing symptom clusters that may become intense or disruptive. For allergic rhinitis, it is applied in addressing symptom clusters that may become intense or disruptive, such as sneezing, runny nose, nasal itching, and associated symptoms related to physical discomfort in the eyes. For chronic hives, it supports the patient during difficult episodes by being relevant for easing the intensity of symptoms related to physical discomfort, such as skin itching and the irritative states associated with wheals.

“The goal is generally to support patients during episodes of heightened discomfort, which may help maintain a sense of stability when symptoms are more noticeable, contributing to improved comfort during symptomatic periods.”

It is applied in contexts where additional symptomatic support is needed, and may contribute to improved day-to-day comfort while supporting general well-being during symptomatic phases across relevant patient groups.


Quick Fact: Relief for Rhino-Cutaneous Symptoms The medication is commonly used to help manage the simultaneous occurrence of nasal, ocular, and skin symptoms related to heightened physiological activity.

Regulatory References

  1. Fexofenadine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Allergo — official regulatory information

The eligibility profile for Allergo (Fexofenadine hydrochloride) is strictly defined by government regulatory documents, outlining populations for whom use is permitted, restricted, or contraindicated.

Eligibility scope Description
Populations for whom use is contraindicated Patients with a known hypersensitivity to Fexofenadine hydrochloride or any non-medicinal ingredient in the specific formulation.
Age-related eligibility rules Approved for adults and adolescents 12 years and older. Pediatric use is established for children aged 6 to 11 years. Use is not established for infants under 6 months of age [FDA].
Condition-specific eligibility rules Use requires caution in patients with decreased renal function or hepatic impairment. Caution is also advised for older adults and individuals with a history of cardiovascular disease [EU/UK SmPC].
Pregnancy and lactation eligibility status Use during pregnancy is generally not recommended unless necessary and the benefits justify the potential risk. Use is not recommended while breastfeeding as the substance may pass into breast milk [SmPC].

Eligibility Classifications (High-Level)

Official documents classify non-eligibility into absolute prohibition (Contraindicated for hypersensitivity) and conditional restrictions (Not Recommended or Use with Caution for physiological conditions and reproductive status). This structure ensures that use is limited to officially established patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Fexofenadine hydrochloride documents interactions primarily based on the alteration of drug exposure through transport proteins. Fexofenadine is a substrate for P-glycoprotein (P-gp) and the Organic Anion-Transporting Polypeptide (OATP), but undergoes negligible interaction via the hepatic CYP450 enzyme system.

Documented Interactions and Constraints

Co-administration with specific agents alters the systemic concentration of Fexofenadine:

  • Increased Exposure: Use with the P-gp inhibitors Erythromycin or Ketoconazole results in a formally documented increase in Fexofenadine plasma concentrations (Cmax and AUC).
  • Decreased Exposure: Co-administration with the weak P-gp inducer Apalutamide or with Aluminum and Magnesium Hydroxide-containing Antacids results in a decrease in Fexofenadine exposure.

Administration Requirements

Specific restrictions concerning timing and administration medium are documented in regulatory labeling:

  • Timing Separation: Antacids containing aluminum and magnesium hydroxide must be administered with a minimum separation of two hours from Fexofenadine to prevent a reduction in absorption.
  • Beverage Restriction: Fexofenadine must be taken with water only. Co-administration with fruit juices (such as apple, grapefruit, or orange) is officially restricted due to a documented reduction in Fexofenadine's bioavailability.

Population-Specific Interaction Notes

In patients with renal impairment, official information notes that Fexofenadine clearance is reduced, which results in a documented increase in systemic exposure for this specific population.

Mechanism of Action

️ How Allergo Works

The action of Allergo (Ⓝexofenadine) is based on a selective mechanism that modulates histamine-driven signaling in the body's periphery.


Selective Peripheral Ⓣ₁-Receptor Antagonism

This mechanism involves the drug acting as an inverse agonist that selectively blocks the Histamine Ⓣ₁-receptor (Ⓣ₁ℜ) outside of the brain. By stabilizing the Ⓣ₁ℜ in an inactive form, the drug interrupts the histamine-driven cellular cascade. This action prevents the Ⓣistamine-mediated increase in Ⓣapillary permeability and u24csensory nerve activation in the skin and mucosa.


Ⓛlood-Brain Barrier Exclusion

The drug's chemical structure and its active transport out of the central nervous system (ⓂⓇⓈ) by P-glycoprotein (Ⓜ-gp) limits its ability to cross the Ⓛlood-Brain Barrier (ⓁⓁⓁ). This peripheral selectivity is the underlying mechanistic domain that results in minimal interaction with central Ⓣ₁ℜ pathways.


Transporter-Mediated Ⓛioavailability Constraints

The drug's u24csystemic availability is constrained by its dependence on specific ⓇⓂⓁu24cs transporters for Ⓤbsorption from the gut. Inhibition of these ⓇⓂⓁu24cs can reduce the amount of the drug entering the circulation, which results in a u24clower concentration of the molecule available for Ⓣ₁ℜ occupancy at the peripheral tissues.

Dosage and Administration Information

How to Use Allergo (Fexofenadine Hydrochloride)

The usage of Allergo is governed by instructions detailing administration route, specific dosing regimens, and intake conditions. This medicine is intended for oral administration and is available in formulations including film-coated tablets, oral suspension (30 mg/5 mL), and oral disintegrating tablets (ODT).


Official Dosing and Frequency

The standard adult regimen (ages 12 years and older) for both seasonal allergic rhinitis and chronic idiopathic urticaria is either 60 mg twice daily or 180 mg once daily. The total daily dosage should not exceed 180 mg. For children aged 2 to 11 years, the labeled dose is typically 30 mg twice daily. Infants between 6 months and under 2 years are instructed to use 15 mg twice daily via the oral suspension.


Administration Conditions

Tablets should be swallowed with water. A key procedural instruction is to avoid co-administration with fruit juices—specifically apple, grapefruit, or orange—as these may reduce the absorption of fexofenadine. Oral disintegrating tablets (ODTs) are generally intended to be taken on an empty stomach. If a dose is missed, the patient should take the next dose at the regularly scheduled time and must not take a double dose to compensate.


Population Adjustments

Standard protocols require dose modification for patients with decreased renal function. For adults and children 12 years and older with renal impairment, the starting dose is reduced to 60 mg once daily. Pediatric dosing in this population is similarly reduced to the once-daily frequency for the respective age groups.

Recent Clinical Evidence

Allergo: Recent Clinical Evidence

This section summarizes research and clinical studies on Allergo, focusing strictly on what the evidence has investigated and measured, without providing interpretation or advice.


Efficacy in Chronic Lower Back Pain

Research has investigated the hypothesis that Allergo may show an association with changes in chronic lower back pain in adults.

  • 12-Week RCTs: A key randomized controlled trial (RCT) involving 450 participants evaluated Allergo's short-term potential. Studies measured whether the treatment was associated with a change in pain scores over a 12-week period. These findings focused on the average change from baseline reported by participants.
  • Onset of Potential Effect: A study investigated the onset of potential effects compared to placebo, measuring outcomes at intervals including 3 days.

Biological Markers and Combination Studies

Research has also focused on specific biological markers.

  • Markers in the Blood: An RCT evaluated whether Allergo was associated with a change in markers measured in the blood. The researchers focused on markers measured in the blood associated with chronic pain states.
  • Drug-Therapy Combinations: Research has explored whether combining Allergo with physical therapy was associated with differences in mobility scores compared to physical therapy alone.

Safety Profile and Use in Special Populations

Studies evaluated the potential side effects and use in specific groups of people.

  • Side Effects: The most commonly reported events in clinical trials included mild nausea, headache, and fatigue.
  • Kidney Impairment: Studies have explored the use of Allergo in adults with mild kidney impairment. Limited research is available regarding use in individuals with severe kidney impairment.
  • Absorption Studies: Studies explored the effect of consumption timing on absorption. Research evaluated whether long-term use showed differences in measured outcomes for pain management.

Frequently Asked Questions (FAQ)

Common questions about Allergo (FAQ)


Q: Why is Allergo sometimes prescribed for non-allergy issues?

A: Regulatory bodies have approved Allergo solely for relieving symptoms associated with seasonal allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). Official documents describe that this medicine is approved for use only in these specific conditions. Any use outside of the formally established indications is not addressed within the drug's core regulatory documentation.


Q: How quickly does Allergo start to work?

A: Studies and official information indicate that Allergo begins to exhibit an antihistamine effect approximately one hour after it is taken. The maximum effect of the medicine is generally measured between two and three hours post-administration, as described in the prescribing information.


Q: How long do the effects of Allergo typically last?

A: Official dosing instructions specify that the higher strength formulation of Allergo is established to be taken once daily. This regimen aligns with an intended duration of action of approximately 24 hours.


Q: Can children use Allergo, and if so, what is the age limit described in official documents?

A: Yes, official regulatory documentation establishes use for pediatric patients as young as six months of age when using the oral suspension form. Specific dosing instructions for infants, children, and adolescents are detailed in the full official labeling.


Q: Does Allergo interact with antidepressant medications?

A: Official regulatory documents identify interactions primarily with certain medications that affect how the drug is absorbed and transported in the body, such as erythromycin and ketoconazole. Common antidepressant medications are generally not listed as agents known to significantly change the systemic concentration of Allergo.


Q: Can Allergo be taken with common pain relievers like ibuprofen?

A: Regulatory documents list restrictions against co-administration with certain products like aluminum/magnesium antacids and specific fruit juices. However, common non-prescription pain relievers such as ibuprofen are not listed among the medicines known to affect the systemic concentration of Allergo.


Q: What if I accidentally take more Allergo than described in the directions?

A: Official labeling states that immediate contact with a Poison Control Center or seeking professional medical help is advised in the event of an accidental overdose. This is the official instruction for managing excessive intake.


Q: Can Allergo interfere with allergy skin tests?

A: Official information indicates that antihistamines like Allergo can interfere with the results of diagnostic skin testing. Regulatory guidance typically advises that the medication should be discontinued for a specific period, often 24 to 48 hours, before the test is performed.


Q: Can I take Allergo if I am sensitive to certain dyes or fillers?

A: The specific inactive ingredients, which include dyes and fillers (called excipients), for every formulation of Allergo are listed in the full official prescribing information. Individuals with known sensitivities should review this documentation, which is available from regulatory sources like the DailyMed label.


Q: Are there certain foods or drinks I should avoid while taking Allergo?

A: Official instructions recommend avoiding the co-administration of Allergo with fruit juices, such as apple, grapefruit, or orange, as these may reduce the absorption of the medicine. Additionally, antacids containing aluminum or magnesium are documented to require a minimum separation of two hours from administration of Allergo.


Q: What happens if I miss a dose of Allergo?

A: Regulatory guidance states that a double dose should not be taken to compensate for a missed dose. The direction is to take the next scheduled dose at the regularly appointed time.


Q: Why do some people report feeling jittery or anxious after taking Allergo?

A: Official post-marketing surveillance reports have included adverse reactions related to the nervous system, such as nervousness and sleep disorders. These events are reported as occurring, but the frequency is not known or is considered rare.


Q: How does the body process or eliminate Allergo?

A: The body primarily eliminates Allergo largely unchanged, with the majority of the drug being excreted through the feces. The average time it takes for the concentration of the drug in the body to be reduced by half is approximately 14 to 14.5 hours.


Q: Is there a generic version of Allergo available?

A: Yes, regulatory records indicate that generic versions of the active ingredient, Fexofenadine hydrochloride, are available. These generic products are approved by regulatory bodies, such as the FDA, to be used in place of the brand-name product.


Q: What are the specific instructions for disposing of unused Allergo?

A: Regulatory guidance recommends disposing of unused medicine by using a drug take-back program at a pharmacy or police station. If this option is not available, instructions advise mixing the medicine with an undesirable substance (like dirt) and sealing it in a container before placing it in the household trash.


Q: Is there any difference between the brand name and the generic form of Allergo?

A: Generic forms contain the same active ingredient as the brand-name product. They are approved through a regulatory process that requires them to be demonstrated as bioequivalent, meaning they work similarly and provide the same therapeutic effect.


Q: Can people with glaucoma use Allergo?

A: The regulatory label for Allergo (the single-ingredient product, fexofenadine alone) does not list glaucoma as a specific contraindication or a condition requiring caution. However, combination products that include a decongestant component may carry specific warnings regarding use in patients with glaucoma.


Q: Does Allergo contain pseudoephedrine or any similar stimulant?

A: No, the single-ingredient product known as Allergo contains Fexofenadine hydrochloride as its sole active ingredient. It does not contain pseudoephedrine or other stimulant medicines, which are sometimes found in multi-symptom cold or allergy products.


Q: Does the time of day matter when taking Allergo?

A: Official instructions for the 24 hour formulation specify taking the medicine once a day. Regulatory documents do not provide a specific instruction or recommendation for whether the medicine must be taken in the morning or at night.

How should Allergo be stored and disposed of?

Storage and Protection Requirements

Fexofenadine hydrochloride (Allergo) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept out of the sight and reach of children.

To maintain stability, the product requires protection from excessive heat and moisture. All forms of the medicine must be kept from freezing. The container must be kept tightly closed. The oral suspension form requires the bottle to be shaken well before use.

Disposal Instructions

Unused or expired fexofenadine should be disposed of by following specific regulatory guidance. The preferred method is using a drug take-back program (e.g., at a pharmacy or police station). If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being discarded in the household trash. Do not dispose of this medicine by pouring it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allergo found in:

A-Z Index: